Bio-Rad Laboratories Inc. (NYSE:BIO) was up 3% during trading on Monday . The stock traded as high as $149.95 and last traded at $149.38, with a volume of 72,966 shares. The stock had previously closed at $145.09.

Several equities research analysts have recently commented on BIO shares. Zacks Investment Research lowered Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a research note on Tuesday, May 10th. Jefferies Group restated a “buy” rating on shares of Bio-Rad Laboratories in a research note on Wednesday, June 8th.

The firm has a 50-day moving average of $143.02 and a 200 day moving average of $138.70. The stock has a market capitalization of $4.29 billion and a P/E ratio of 39.94.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, May 5th. The company reported $0.42 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.60 by $0.18. During the same period last year, the business posted $0.61 EPS. The business had revenue of $471.20 million for the quarter, compared to the consensus estimate of $463.90 million. The firm’s quarterly revenue was down .3% compared to the same quarter last year. On average, analysts expect that Bio-Rad Laboratories Inc. will post $3.40 earnings per share for the current fiscal year.

Several large investors recently bought and sold shares of the company. Bank of Montreal Can increased its stake in Bio-Rad Laboratories by 13.1% in the fourth quarter. Bank of Montreal Can now owns 10,021 shares of the company’s stock valued at $1,390,000 after buying an additional 1,163 shares during the last quarter. Liberty Mutual Group Asset Management Inc. increased its stake in Bio-Rad Laboratories by 51.4% in the fourth quarter. Liberty Mutual Group Asset Management Inc. now owns 13,320 shares of the company’s stock valued at $1,846,000 after buying an additional 4,523 shares during the last quarter. Comerica Bank increased its stake in Bio-Rad Laboratories by 0.3% in the fourth quarter. Comerica Bank now owns 15,009 shares of the company’s stock valued at $1,959,000 after buying an additional 38 shares during the last quarter. Principal Financial Group Inc. increased its stake in Bio-Rad Laboratories by 3.5% in the fourth quarter. Principal Financial Group Inc. now owns 66,434 shares of the company’s stock valued at $9,212,000 after buying an additional 2,238 shares during the last quarter. Finally, Morgan Stanley increased its stake in Bio-Rad Laboratories by 356.6% in the fourth quarter. Morgan Stanley now owns 71,554 shares of the company’s stock valued at $9,921,000 after buying an additional 55,884 shares during the last quarter.

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.